Delving into the Latest Updates on Ayerst Laboratories, Inc. with Synapse

Overview

Tags

Immune System Diseases

Digestive System Disorders

Respiratory Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4
Chemical drugs	1

Top 5 Target	Count

NET(Norepinephrine transporter)	1
PGE2(Prostaglandin E2)	1
H2 receptor(Histamine H2 receptor)	1
α-adrenergic receptor(Alpha adrenergic receptor)	1
ADRA1(Adrenergic receptor alpha-1)	1

(±)-AY-22469 (I) [50266-09-6] and its ent [50454-71-2] and nat isomer [33813-84-2] inhibited gastric acid secretion in rats although the volume of gastric juice was unchanged; the ent isomer (ED50 mg/kg) was 2.8 times as potent as the nat isomer.The incidnce of diarrhea in mice was low with both isomers (25% at 240 mg/kg).

12 Apr 2011·Journal of Pharmacy and PharmacologyQ3 · MEDICINE

Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2-[p-chlorophenyl-2-(pyridyl)-hydroxymethyl] imidazoline maleate (Sch-12650)

Q3 · MEDICINE

Article

Author: Lippmann, W

The i.p. administration of the title compound (I, 1.25-10.0 mg/kg) inhibited the uptake of noradrenaline-3H by rat heart by 14-72% but did not cause its increase release.I was similar in potency to imipramine, as the noradrenaline-3H level was decreased to ∼50% by ∼4 mg/kg of either compoundI (5.0 mg/kg, i.p.) decreased gastric acid secretion by 65%, whereas imipramine (5.0 mg/kg) decreased gastric acid secretion by 71%.In pentagastrin-induced gastric acid secretion, I (5.0 mg/kg, i.p.) inhibited gastric acid secretion by 88%, a similar inhibition being noted with imipramine (10 mg/kg, i.p.).

12 Apr 2011·Journal of Pharmacy and PharmacologyQ3 · MEDICINE

Diethyldithiocarbamate and structurally-related compounds and the uptake and release of noradrenaline in the heart of the rat

Q3 · MEDICINE

Article

Author: Lloyd, K ; Lippmann, W

Pretreatment (125 mg/kg, i.p.) with disulfiram and diethyldithiocarbamate, inhibitors of cardiac dopamine β-hydroxylase, as well as with the structurally related compounds, ethyldithiocarbamate, dimethyldithiocarbamate, tetramethylthiuram disulfide, and tetramethylthiuram monosulfide, had no significant effect on the uptake, short-term storage, or release of exogenously administered tritiated noradrenaline in the rat heart.

100 Deals associated with Ayerst Laboratories, Inc.

Login to view more data

100 Translational Medicine associated with Ayerst Laboratories, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AY-22093 ( PGE2 )	Bronchial Spasm More	Preclinical
Atiprosin ( α-adrenergic receptor )	Hypertension More	Preclinical
AY-29315 ( H2 receptor )	Peptic Ulcer More	Preclinical
Tandamine ( NET )	Depressive Disorder More	Preclinical
AY-30191 ( ADRA1 )	-	Preclinical